NEWS
Croda chief awarded CBE in King’s birthday honours
Croda chief executive Steve Foots has been appointed Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours for services to the chemical and life sciences industries. Foots has been with Croda for
35 years, having joined the British speciality chemicals maker as a graduate trainee in 1990. Born in Sunderland in the north-east of England, Steve Foots studied chemistry at the University of York. Foots became Croda chief
executive in 2012, the same year the company joined the FTSE 100 Index of the London Stock Exchange. He has overseen Croda’s global
expansion, its contribution to the Pfizer-BioNTech Covid-19 vaccine and the establishment the Croda Foundation, solely funded by Croda, that has so far committed over £5m to charitable projects. Foots is also co-chair of a joint
government/industry sector council for the chemical industry in the UK.
“Needless to say, I am incredibly
proud and honoured to have been appointed a CBE in the King’s Honours Birthday List,” he said. “This award is recognition of
Croda’s success, the company that I have been lucky enough to lead for the past 13 years, with its world- leading science and incredibly talented people – the lifeblood of this great business,” he added. “It seems particularly fitting that
Steve received this honour as we celebrate our centenary year,” said a spokeswoman. “Congratulations, Steve, and
thank you for your dedication to Croda, your inspiration and support to our people,” she added.
Nick Challoner lands Ingenza top job
British contract research, development and manufacturing organisation (CRDMO) Ingenza has appointed Nick Challoner as its chief executive officer, effective 1 October. Challoner brings over 30
years of experience in business leadership, innovation, and commercial strategy and execution across the chemical and biotechnology sectors, and has operated internationally in Europe, the Americas and Asia Pacific. He most recently served as
group chief scientific officer (CSO) at Croda International, a FTSE 100 company. Prior to becoming CSO, he
held the position of President of Life Sciences and, following
the acquisition of a new class of lipid delivery systems, he led the business through the scale-up and regulatory approval for mRNA delivery components used by Pfizer/BioNTech for the Comirnaty COVID-19 vaccine, leading to sales of $300m. He succeeds Ingenza founder
Ian Fotheringham, who will be elevated to President at Ingenza. “Stepping into the role of
President will allow me to focus
fully on advancing key pillars of our growth plans,” said Fotheringham. “With Nick’s leadership and
expertise now complementing the experience of Ingenza’s board, the company is in an excellent position for the journey ahead.” Challoner added: “I am deeply
honoured by the opportunity to lead Ingenza at such an exciting time.
“My goal is to strengthen the
company’s position as a leading strategic partner in the CRDMO sector, driving operational excellence, innovation, quality and transformative growth, as well as investing further in the development of the fantastic team at Ingenza to enable even greater performance for our customers.”
Elementis appoints Stijn Dejonckheere CCO Dejonckheere holds master’s
UK cosmetic ingredient maker Elementis has promoted Stijn Dejonckheere to the role of chief commercial officer. The Belgian will lead the
Personal Care and Performance Specialties businesses of the FTSE250 company. Dejonckheere was previously
senior vice-president for Personal Care since July 2020, and before that was director of sales for Personal Care.
www.personalcaremagazine.com
degrees in Bio-Engineering from Ghent University in Belgium and Agro-Management from Montpellier SupAgro in France. He is also a graduate of the
Executive Development Program from the Wharton School. The move follows the
appointment of Elementis’s new chief executive officer, Luc van Ravenstein, who took over from Paul Waterman on 29 April.
The British firm recently
completed the sale of its talc business to IMI Fabi for $121m.
Brenntag names Jens Birgersson next chief exec
German speciality ingredient and chemical distributor Brenntag has appointed Jens Birgersson as its next chief executive officer, effective 1 September. Swedish-born Birgersson most
recently served as President and CEO of Rockwool Group, Denmark and previously held senior management positions at Imerys and ABB. He succeeds Christian
Kohlpaintner, who decided not to renew his contract as communicated in November. Richard Ridinger, Chairman of
the Supervisory Board of Brenntag, said: “With Jens Birgersson we have been able to appoint an internationally very experienced business leader as our new CEO. In combination with his operational excellence orientation, he brings all the skills needed to steer Brenntag’s further growth path and strategic development. “His mission at Brenntag
will be to further improve the company’s operational performance, execute its growth strategy and to continue Brenntag’s ambitious transformation as a key prerequisite for sustainable growth and long-term success.” Birgersson added: “I am
honoured by the trust the Supervisory Board has placed in me. As the global number one and a DAX 40 company, Brenntag enjoys a strong reputation, unique selling proposition and high visibility, both nationally and internationally. “I am excited to lead this well- positioned and high-potential company into its next chapter. I look forward to the opportunity to join my colleagues on the Management Board and the entire Brenntag team in September.
August 2025 PERSONAL CARE
9
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114
